Ali Afshar-Oromieh, Presenter: Nothing to Disclose

Eleni Avtzi, Abstract Co-Author: Nothing to Disclose

Matthias Eder, Abstract Co-Author: Nothing to Disclose

Michael Eisenhut, Abstract Co-Author: Nothing to Disclose

Tim Holland-Letz, Abstract Co-Author: Nothing to Disclose

Silvan Boxler, Abstract Co-Author: Nothing to Disclose

Boris Hadaschik, Abstract Co-Author: Nothing to Disclose

Clemens Kratochwil MD, Abstract Co-Author: Nothing to Disclose

Frederik Lars Giesel MD, MBA, Abstract Co-Author: Nothing to Disclose

Wilko Weichert, Abstract Co-Author: Nothing to Disclose

Juergen Debus MD, PhD, Abstract Co-Author: Nothing to Disclose

Uwe Haberkorn MD, Abstract Co-Author: Nothing to Disclose

Since the introduction of PET-imaging with the 68Ga-labelled PSMA ligand HBED-CC, this highly promising method has rapidly spread out across many countries. There exists evidence, that this imaging method might be a significant step forward in the diagnosis of prostate cancer (PCa). The aim of this study was to evaluate the role and valence of the 68Ga-PSMA-PET/CT in the diagnosis of PCa.

We performed a retrospective analysis of 319 patients who were investigated by 68Ga-PSMA-PET/CT. Mean Gleason Score (GSC) was 7.5, median PSA level 4.6 ng/ml. Possible influence of several factors (PSA level, GSC, hormonal therapy, age, applied amount of injected tracer) were evaluated. 41 Patients were investigated by biopsy after PET/CT. Tracer uptake was measured in 901 representative tumor lesions.

In 82.8% of the patients at least one lesion indicative for PCa was detected. Current hormonal therapy had no negative influence on the detection rate. High amounts of injected tracer did not improve the probability to detect tumor suspicious lesions. Tumor detection showed a positive association with PSA level. GSC did not show an influence on tumor detection. Mean SUVmax of all tumor lesions was 13.3 ± 14.6. Only three of all histopathologically investigated lesions were false negative in PSMA-PET/CT, all others (n=304) were true negative and positive.

68Ga-PSMA-PET/CT can detect PCa with high sensitivity. In addition, the tracer is highly specific for PCa. Detection of PCa can be improved by higher PSA level. Current hormonal therapy did not influence the detection rate negatively. GSC did not show an influence on tumor detection.

Introduced in 2011, PET-imaging with the 68Ga-labelled PSMA-ligand HBED-CC has rapidly spread out across many countries. This new method of imaging is thought to be a significant step foreward in the diagnosis of recurrent prostate cancer.

Afshar-Oromieh, A, Avtzi, E, Eder, M, Eisenhut, M, Holland-Letz, T, Boxler, S, Hadaschik, B, Kratochwil, C, Giesel, F, Weichert, W, Debus, J, Haberkorn, U, The Role of PET/CT Imaging with the 68Ga-labelled PSMA-ligand HBED-CC in the Diagnosis of Recurrent Prostate Cancer.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14014836.html